Leverage Gene Addition, Silencing & Editing Approaches to Revolutionize Development & Delivery of Gene Therapies to the Eye

Welcome to the 5th Gene Therapy for Ophthalmic Disorders Summit

Harness Genetic Medicine for Treatment of Rare & Common Eye Diseases

Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.

Join 100+ industry leaders at the 5th Gene Therapy for Ophthalmic Disorders Summit to uncover cutting-edge gene therapy breakthroughs. Harness the latest developments in vector engineering to target retinal cells more effectively with higher transduction efficiency. Understand the crucial role of endpoint selection to clearly demonstrate product efficacy to the FDA & EMA. Understand the risk-benefit profiles of different ocular administration routes including intravitreal, subretinal, and suprachoroidal delivery to choose the best option for your specific indication. Learn from successful clinical trials as well as where trials have fallen short of expectations to take forward crucial lessons learnt on progressing a gene therapy rapidly through the clinic without compromising on safety.

Our World-Class Speaker Faculty Includes:

download
company-sanofi
ASTellas logo-440px
kR-M7VLB_400x400
images
Janssen_Pharmaceuticals_logo.svg
AbbVie_logo.svg
DS_Logo_Special_format_4color_rgb_120206
Spark_Therapeutics_Label
ARWR_Logo

Previous Attending Companies Include:

Gene Therapy for Ophthalmic Disorders Companies Attending